Home Health Ship2B Ventures invests in a digital cancer therapy platform

Ship2B Ventures invests in a digital cancer therapy platform

  • The Barcelona venture capital firm has participated in an investment round closed by Fosanis of 10 million euros

The impact venture capital firm Ship2B Ventures -based in Barcelona- has participated in the investment round that the digital health company Fosanis has closed, worth 10 million euros. The German company has developed Mika, the first prescription digital therapy platform for all oncological diseases.

The investment round has been led by the Swiss company Debiopharm, and has had other ‘business angels’ and shareholders of the company. Specifically, the impact manager based in Germany and England, Ananda Impact Ventures, and the venture capital firm Equity Pitcher have joined. In this way, it seeks to expand the company’s impact to new international territories.

Read:  What is severe apnea? The disease suffered by Jorge Javier Vázquez

According to the co-founders of Mika, Gandolf Finke Y Jan Simon Raue, the importance of digital health and digital therapies in particular “is increasing globally”. The co-founders have highlighted that the investment round marks an important milestone in the company’s history, allowing it to scale the Digital Oncology Therapeutics platform and positioning it on an international scale.

For her part, the co-founder and ‘general partner’ of Ship2B Ventures, Maite Fiblaexplained how proud the company is to improve the lives of many more cancer patients: “Not only does its mission fit our parameters of what an impact start-up should be, we are also totally committed to it” .

Read:  Catalonia to vaccinate pregnant women against flu and the fourth dose of covid

Following this transaction, Mika joins CodeOp, Rosita Longevity, LiveLink Motor and Sycai Medical as the first impact start-ups owned by Ship2B Ventures through BSocial Impact Fund, the largest impact fund for start-ups in Spain , supported by the EIF and Banco Sabadell, which has 55 million euros after its final closing.


Mika combines monitoring and training based on artificial intelligence, including scientifically proven methods and therapy management techniques. Daily check-ins “allow continuous monitoring of distress levels and symptoms,” while a personalized training program provides scientifically validated multimedia elements and psycho-oncology interventions, according to the company. Some 20 million people were diagnosed with cancer worldwide last year, according to the World Health Organization (WHO).

Previous articleWorld governments and paid hackers, the main source of newly discovered Android exploits
Next articleThe MOE warns of irregularities during the presidential elections this Sunday in Colombia